down arrow

Medicenna Therapeutics Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA58490H1073
CAD
1.56
-3.54 (-69.41%)

Dec 04

TSE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.501.68

52 Week

0.782.16
Valuation
Technical
Day's Volume

CASH

239.81 k

Shareholding (Dec 2024)

FII

12.62%

Held by 29 FIIs

DII

87.38%

Held by 1 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 124 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.39

stock-summary
Return on Equity

-141.81%

stock-summary
Price to Book

8.44

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-69.41%
0%
-69.41%
6 Months
-37.6%
0%
-37.6%
1 Year
47.18%
0%
47.18%
2 Years
51.6%
0%
51.6%
3 Years
-30.34%
0%
-30.34%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Medicenna Therapeutics Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-183.72%
EBIT to Interest (avg)
-17.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.30
Sales to Capital Employed (avg)
0
Tax Ratio
9.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
13.02%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.81
EV to EBIT
-2.16
EV to EBITDA
-2.17
EV to Capital Employed
-8.68
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-141.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 29 Foreign Institutions (12.62%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -36.11% vs -24.14% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.50",
          "val2": "-4.00",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.30",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.90",
          "val2": "-3.60",
          "chgp": "-36.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 53.73% vs -155.00% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.60",
          "val2": "-18.70",
          "chgp": "-15.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "6.30",
          "val2": "-7.90",
          "chgp": "179.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.80",
          "val2": "-25.50",
          "chgp": "53.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.50
-4.00
-37.50%
Interest
0.00
0.00
Exceptional Items
1.30
-0.00
Consolidate Net Profit
-4.90
-3.60
-36.11%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -36.11% vs -24.14% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-21.60
-18.70
-15.51%
Interest
0.00
0.00
Exceptional Items
6.30
-7.90
179.75%
Consolidate Net Profit
-11.80
-25.50
53.73%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 53.73% vs -155.00% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Medicenna Therapeutics Corp. stock-summary
stock-summary
Medicenna Therapeutics Corp.
Pharmaceuticals & Biotechnology
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Company Coordinates stock-summary
Company Details
2 Bloor St W 7th Floor , TORONTO ON : M4W 3E2
stock-summary
Tel: 1 416 6485555
stock-summary
https://www.medicenna.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."